{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:06:22Z","timestamp":1781269582876,"version":"3.54.1"},"reference-count":101,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Nucleic Acid Therapeutics"],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:p>\n                    Delivery to the target site and adversities related to off-target exposure have made the road to clinical success and approval of antisense oligonucleotide (AON) therapies challenging. Various classes of AONs have distinct chemical features and pharmacological properties. Understanding the similarities and differences in pharmacokinetics (PKs) among AON classes is important to make future development more efficient and may facilitate regulatory guidance of AON development programs. For the class of 2\u2032-\n                    <jats:italic toggle=\"yes\">O<\/jats:italic>\n                    -methyl phosphorothioate (2OMe PS) RNA AONs, most nonclinical and clinical PK data available today are derived from development of exon skipping therapies for Duchenne muscular dystrophy (DMD). While some publications have featured PK aspects of these AONs, no comprehensive overview is available to date. This article presents a detailed review of absorption, distribution, metabolism, and excretion of 2OMe PS AONs, compiled from publicly available data and previously unpublished internal data on drisapersen and related exon skipping candidates in preclinical species and DMD patients. Considerations regarding drug\u2013drug interactions, toxicokinetics, and pharmacodynamics are also discussed. From the data presented, the picture emerges of consistent PK properties within the 2OMe PS class, predictable behavior across species, and a considerable overlap with other single-stranded PS AONs. A level of detail on muscle as a target tissue is provided, which was not previously available. Furthermore, muscle biopsy samples taken in DMD clinical trials allowed confirmation of the applicability of interspecies scaling approaches commonly applied in the absence of clinical target tissue data.\n                  <\/jats:p>","DOI":"10.1089\/nat.2019.0805","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T11:55:53Z","timestamp":1566302153000},"page":"305-322","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["The Pharmacokinetics of 2\u2032-\n                    <i>O<\/i>\n                    -Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy"],"prefix":"10.1177","volume":"29","author":[{"given":"Sieto","family":"Bosgra","sequence":"first","affiliation":[{"name":"BioMarin Nederland BV, Leiden, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sipkens","sequence":"additional","affiliation":[{"name":"BioMarin Nederland BV, Leiden, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjef","family":"de Kimpe","sequence":"additional","affiliation":[{"name":"BioMarin Nederland BV, Leiden, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathaline","family":"Den Besten","sequence":"additional","affiliation":[{"name":"BioMarin Nederland BV, Leiden, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Datson","sequence":"additional","affiliation":[{"name":"BioMarin Nederland BV, Leiden, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"van Deutekom","sequence":"additional","affiliation":[{"name":"BioMarin Nederland BV, Leiden, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.070"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0656"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3625"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw533"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio839"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010716-104558"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2012.0340"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.14.116"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.023"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1239"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607199"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3765"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1039\/9781788015714-00474"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2012.0383"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/2168479015592195"},{"key":"e_1_3_5_17_2","first-page":"183","article-title":"Basic principles of pharmacokinetics of antisense oligonucleotide drugs","author":"Levin AA","year":"2008","unstructured":"Levin AA, , Yu RZ, and Geary RS. (2008). Basic principles of pharmacokinetics of antisense oligonucleotide drugs. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed. Crooke ST, ed., CRC Press, Carlsbad, CA, pp 183\u2013215.","journal-title":"Antisense Drug Technology: Principles, Strategies and Applications"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.01.008"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.72"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.1"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073108"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011367"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.09.004"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70195-4"},{"issue":"11","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"e0161955","DOI":"10.1371\/journal.pone.0161955","article-title":"Long-term efficacy, safety, and pharmacokinetics of drisapersen in duchenne muscular dystrophy: results from an open-label extension study","volume":"2","author":"Goemans NM","year":"2016","unstructured":"Goemans NM, , Tulinius M, , van den Hauwe M, , Kroksmark AK, , Buyse G, , Wilson RJ, , van Deutekom JC, , de Kimpe SJ, , Lourbakos A, and Campion G. (2016). Long-term efficacy, safety, and pharmacokinetics of drisapersen in duchenne muscular dystrophy: results from an open-label extension study. PLoS One, 2; 11:e0161955.","journal-title":"PLoS One"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.11.013"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.579"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.10.004"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/102.1.147"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07815-7"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0682"},{"key":"e_1_3_5_32_2","first-page":"305","article-title":"Pharmacokinetic\/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man","author":"Geary RS","year":"2008","unstructured":"Geary RS, , Yu RZ, , Siwkowski A, and Levin AA. (2008). Pharmacokinetic\/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed. Crooke ST, ed. CRC Press, Carlsbad, CA, pp 305\u2013326.","journal-title":"Antisense Drug Technology: Principles, Strategies and Applications"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.07.001"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0649"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.69"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2013.0463"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0641"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0694"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0727"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0759"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2010.02.012"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.263"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.25.12.1111"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0707795"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201010436"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00924-7"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1482279"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt341"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60756-3"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-015-0070-6"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1288"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.009"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171127"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.7.3.189.4007"},{"key":"e_1_3_5_56_2","first-page":"263","article-title":"Pegaptanib in the treatment of wet, age-related macular degeneration","volume":"1","author":"Vinores SA","year":"2006","unstructured":"Vinores SA. (2006). Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine, 1:263\u2013268.","journal-title":"Int J Nanomedicine"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2012.0398"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/ard.1991.1.141"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.1.1998.8.35"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(99)00140-2"},{"key":"e_1_3_5_61_2","first-page":"117","volume":"10","author":"Eckstein F","year":"2000","unstructured":"Eckstein F. (2000). Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev, 10:117\u2013121.","journal-title":"Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev"},{"key":"e_1_3_5_62_2","unstructured":"EMA (2012). Guideline on the investigation of drug interactions. CPMP\/EWP\/560\/95\/Rev. 1 Committee for Human Medicinal Products (CHMP) June 2012."},{"key":"e_1_3_5_63_2","unstructured":"FDA (2017). In Vitro Metabolism and Transporter-Mediated Drug-Drug Interaction Studies. Draft Guidance for Industry. FDA CDER October 2017."},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.08.012"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.081729"},{"key":"e_1_3_5_66_2","first-page":"115","article-title":"A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer","volume":"9","author":"Adjei AA","year":"2003","unstructured":"Adjei AA, , Dy GK, , Erlichman C, , Reid JM, , Sloan JA, , Pitot HC, , Alberts SR, , Goldberg RM, , Hanson LJ, et al. (2003). A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res, 9:115\u2013123.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0779"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645080-00003"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200948010-00003"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000101"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2015.0588"},{"key":"e_1_3_5_72_2","first-page":"3458","volume":"102","author":"Heuberger J","year":"2013","unstructured":"Heuberger J, , Schmidt S, and Derendorf H. (2013). When is protein binding important? J Pharm Sci, 102:3458\u20133467.","journal-title":"When is protein binding important? J Pharm Sci"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.09.007"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1089\/ard.1995.5.131"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.2006.16.169"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.04.017"},{"key":"e_1_3_5_77_2","first-page":"327","article-title":"Toxicologic properties of 2'-methoxyethyl chimeric antisense inhibitors in animals and man","author":"Henry SP","year":"2008","unstructured":"Henry SP, , Kim TW, , Kramer-Stickland K, , Zanardi TA, , Fey RA, and Levin AA. (2008). Toxicologic properties of 2'-methoxyethyl chimeric antisense inhibitors in animals and man. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed. Crooke ST, ed. CRC Press, Carlsbad, CA, pp 327\u2013363.","journal-title":"Antisense Drug Technology: Principles, Strategies and Applications"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/gtc.12587"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1210"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep30377"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky397"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki762"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1261\/rna.25706"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv857"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.07.003"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.11.004"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/374546a0"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-018-3272-1"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313505781"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314551840"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.1.1997.7.503"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.5.1617"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)36667-4"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2014.0491"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.219378"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.136"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0666"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0650"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.01.013"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.2.582"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw236"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0739"}],"container-title":["Nucleic Acid Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/nat.2019.0805","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2019.0805","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2019.0805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:01:21Z","timestamp":1777669281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/nat.2019.0805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12,1]]}},"alternative-id":["10.1089\/nat.2019.0805"],"URL":"https:\/\/doi.org\/10.1089\/nat.2019.0805","relation":{},"ISSN":["2159-3337","2159-3345"],"issn-type":[{"value":"2159-3337","type":"print"},{"value":"2159-3345","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}